Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:34 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
NCT01697072 · Amgen · PHASE3 · terminated · last registry update 2016-02-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data Monitoring Committee safety review of study 20070622.” | – | Registry record, Amgen |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HGF within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2017-01-09Phase 3 first posted: Beat AML, LLC, Samalizumab (BAML-16-001-S1) + BI 836858 (BAML-16-001-S2) (NCT03013998)
- 2016-10-06Phase 3 first posted: SWOG Cancer Research Network, Erlotinib Hydrochloride + Rilotumumab (NCT02926638)
- 2016-09-01Results posted on the registry: Ahmad Tarhini, AMG 102 and erlotinib (NCT01233687)
- 2016-04-04Also stopped (terminated): Amgen, Rilotumumab + Placebo (NCT02137343)
- 2015-12-10Results posted on the registry: Katy Peters, AMG 102 + Avastin (NCT01113398)
- 2015-07-20Results posted on the registry: NantBioScience, Inc., Panitumumab + Ganitumab (NCT00788957)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision